Login / Signup

Aztreonam/avibactam activity against a large collection of carbapenem-resistant Enterobacterales (CRE) collected in hospitals from Europe, Asia and Latin America (2019-21).

Helio Silva SaderMariana CastanheiraJohn H KimbroughValerie KantroRodrigo Elisandro Mendes
Published in: JAC-antimicrobial resistance (2023)
Aztreonam/avibactam activity was not adversely affected by clinically relevant CPEs. Our results support aztreonam/avibactam development to treat infections caused by CRE, including MBL producers.
Keyphrases
  • klebsiella pneumoniae
  • gram negative
  • healthcare
  • multidrug resistant